Page 2 - V3 Product Catalog 2016

NewProducts Available from ASD Healthcare
ASD Healthcare is now an authorized distributor for several new products, which are described below. We continuously expand our product lines to make sure you have access to the products you need, when you need them. To verify a product is appropriate for your facility to order, simply call your sales representative. We’re always here to help you.
ADCETRIS®
Manufactured by Seattle Genetics, ADCETRIS (brentuximab vedotin) is indicated for treatment of patients with classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto- HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates; classical HL
at risk of relapse or progression as post-auto-HSCT consolidation; and for patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.
For specific product information, please see page 12 in our Product Catalog.
Exondys 51TM
Manufactured by Sarepta Therapeutics, Exondys 51 (eteplirsen) is the first drug to receive FDA approval to treat patients with Duchenne mus- cular dystrophy (DMD) who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping.
Exondys 51 was approved under the accelerated approval pathway, which provides for the approval of drugs that treat serious or life- threatening diseases and generally provide a meaningful advantage over existing treatments.
For specific product information, please see page 18 in our Product Catalog.
For quick and updated product information on our most popular products, including these new products, please see our Product Catalog on page 3.
See the most up-to-date list of new products available from ASD Healthcare by going to bit.ly/ASDNewProducts!
2 | InsideOut